These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 24041229)
1. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma. Waters AM; Beierle EA Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229 [TBL] [Abstract][Full Text] [Related]
2. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. He J; Gu L; Zhang H; Zhou M Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876 [TBL] [Abstract][Full Text] [Related]
3. MYCN, neuroblastoma and focal adhesion kinase (FAK). Beierle EA Front Biosci (Elite Ed); 2011 Jan; 3(2):421-33. PubMed ID: 21196322 [TBL] [Abstract][Full Text] [Related]
4. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis. Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861 [TBL] [Abstract][Full Text] [Related]
5. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205 [TBL] [Abstract][Full Text] [Related]
6. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562 [TBL] [Abstract][Full Text] [Related]
7. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Calao M; Sekyere EO; Cui HJ; Cheung BB; Thomas WD; Keating J; Chen JB; Raif A; Jankowski K; Davies NP; Bekkum MV; Chen B; Tan O; Ellis T; Norris MD; Haber M; Kim ES; Shohet JM; Trahair TN; Liu T; Wainwright BJ; Ding HF; Marshall GM Oncogene; 2013 Aug; 32(31):3616-26. PubMed ID: 22907436 [TBL] [Abstract][Full Text] [Related]
8. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028 [TBL] [Abstract][Full Text] [Related]
9. Targeting the MYCN effector, FAK, in neuroblastoma. Davidoff AM Cell Cycle; 2010 Mar; 9(6):1026. PubMed ID: 20410685 [No Abstract] [Full Text] [Related]
10. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863 [TBL] [Abstract][Full Text] [Related]
11. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444 [TBL] [Abstract][Full Text] [Related]
12. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Slack A; Shohet JM Cell Cycle; 2005 Jul; 4(7):857-60. PubMed ID: 15917661 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436 [TBL] [Abstract][Full Text] [Related]
15. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277 [TBL] [Abstract][Full Text] [Related]
16. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359 [TBL] [Abstract][Full Text] [Related]